Profil bibliographique

Börje Darpö

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

171Publications signalées

4296Citations signalées

2Affiliations récentes

Institutions déclarées

Clarion University Thermo Fisher Scientific (United States)

Domaines associés

Cardiac electrophysiology and arrhythmiasAtrial Fibrillation Management and OutcomesCardiac Arrhythmias and TreatmentsReceptor Mechanisms and SignalingECG Monitoring and Analysis

Publications récentes

2026 article

How to Replace the TQT Study—The Use of Concentration‐QTc Modeling to Exclude a Small Effect of a Novel Drug on QT Interval: Historical Perspective and Implementation

Börje Darpö, Georg Ferber, Seth C. Hopkins, Karine Litherland et autres

0 citationsThe Journal of Clinical Pharmacology

Accès ouvert 2026 conference-abstract

Leveraging E7386 phase 1 trials for cardiac safety: Gaining concentration-QTc insights to inform early-stage oncology development.

Shriram M. Pathak, Nozomi Hayata, Juanita Lopez, Natalie Cook et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 article

Results of a Phase 1 Study Assessing the Effect of CIN‐102, a Novel Formulation of the Dopamine Receptor Antagonist Domperidone Designed to Treat Gastroparesis, on Cardiac Repolarization in Healthy Volunteers

Mary Bond, Brian Murphy, Brendan Doran, Börje Darpö et autres

2 citationsClinical Pharmacology in Drug Development

Accès ouvert 2026 article

Thorough QT Study on the Effect of Therapeutic and Supratherapeutic Dosing of Givinostat in Healthy Volunteers

Eugenio Mercuri, Barry J. Byrne, Tracey Willis, John Bourke et autres

0 citationsClinical Pharmacology in Drug Development

Accès ouvert 2026 article

Cardiodynamic evaluation of sorfequiline (TBAJ-876): results from a first-in-human study

Börje Darpö, Jerry Nedelman, Rebecca S. Bruning-Barry, Dean Hickman et autres

0 citationsAntimicrobial Agents and Chemotherapy

Accès ouvert 2026 article

No QTcF Prolongation with Sepiapterin: Results From a Thorough QT Study in Healthy Subjects at Therapeutic and Supratherapeutic Doses

Lan Gao, H. Xue, Börje Darpö, Kimberly Ingalls et autres

2 citationsThe Journal of Clinical Pharmacology

2025 conference-abstract

XS003, an amorphous re-formulation of nilotinib, demonstrates improved dose linearity and minimal food effect, reducing the risk of QT-prolongation at fed conditions

Mikael von Euler, Charlotta Liljebris, Magnus Brisander, Per Andersson et autres

0 citationsBlood

Accès ouvert 2025 article

Evaluation of Rusfertide, a Hepcidin Mimetic, on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled Crossover Thorough QT Study in Healthy Participants

Nishit B. Modi, Phillip Dinh, Hongqi Xue, Börje Darpö

1 citationClinical Therapeutics

2025 article

Sample size determination for cardiodynamic ECG assessment using the Concentration-QTc analysis method

Hongqi Xue, Georg Ferber, Ellen Freebern, Börje Darpö

0 citationsJournal of Pharmacokinetics and Pharmacodynamics

2025 article

Replicating clinical placebo effects in computational trials: Bridging the gap between in silico and clinical studies

Paula Dominguez-Gomez, Constantine Butakoff, Georg Rast, Börje Darpö et autres

2 citationsThe Journal of Precision Medicine Health and Disease

2025 article

749-P: Integrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment

Shaheen Tomah, J S James, SARAH K. BROWNE, Börje Darpö et autres

1 citationDiabetes

Accès ouvert 2025 conference-abstract

0837 Evaluation of Cardiac Safety Profile of ALKS 2680 in Healthy Subjects: Concentration-QTc Relationship of ALKS 2680

Jahnavi Kharidia, Börje Darpö, Sergey Yagoda, Alexandra Lovett et autres

0 citationsSLEEP

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Métadonnées interrogées à la demande auprès de OpenAlex (CC0). Sources et limites.